§13800-C. Opioid medication product registration fee
(CONTAINS TEXT WITH VARYING EFFECTIVE DATES)
This section governs opioid medication product registration fees. As used in this section, "unit of an opioid medication" means the lowest identifiable quantity of the opioid medication that is dispensed. [PL 2019, c. 536, §4 (NEW).]
1. Registration fee. Except as provided in subsection 2, a manufacturer that sells, delivers or distributes an opioid medication in this State shall pay an annual registration fee of $250,000 to the board on December 31st of each year.
[PL 2019, c. 536, §4 (NEW).]
2. Exception. A manufacturer that does not sell, deliver or distribute 2,000,000 or more units of an opioid medication within this State in the year in which a registration fee is due is not required to pay the registration fee. To qualify for the exception under this subsection, a manufacturer must demonstrate to the board, by January 31st of the year following the year in which the registration fee is due, in a manner determined by the board, that the manufacturer did not sell, deliver or distribute 2,000,000 or more units of an opioid medication within this State in the year in which the manufacturer seeks to claim the exception. The board may adopt rules to implement this section. Rules adopted pursuant to this subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2‑A.
[PL 2019, c. 536, §4 (NEW).]
3. Calculation of units of an opioid medication sold, delivered or distributed. When calculating the number of units of an opioid medication sold, delivered or distributed by a manufacturer under subsection 2, units of an opioid medication may be excluded when prescribed for the purpose of medication-assisted treatment of substance use disorder. The board periodically shall provide to the Department of Health and Human Services a list of medications exempted under this subsection.
[PL 2019, c. 536, §4 (NEW).]
4. (TEXT EFFECTIVE UNTIL 9/1/23) (TEXT REPEALED 9/1/23) Registration fee review and report. By March 1st of each year following calendar years 2020, 2021 and 2022, the board shall evaluate and report whether the registration fee due under this section and the fee due under section 13724 have affected the prescribing practices of opioid medications by reducing the number of opioid medication prescriptions issued during calendar years 2020, 2021 and 2022 or whether the fees have created any unintended consequences in the availability of opioid medications for the treatment of chronic or intractable pain, to the extent the board has the ability to identify a correlation. The board shall provide the report to the joint standing committee of the Legislature having jurisdiction over health and human services matters, which may report out legislation based upon the report.
This subsection is repealed September 1, 2023.
[PL 2019, c. 536, §4 (NEW).]
SECTION HISTORY
PL 2019, c. 536, §4 (NEW).
Structure Maine Revised Statutes
TITLE 32: PROFESSIONS AND OCCUPATIONS
Chapter 117: MAINE PHARMACY ACT
Subchapter 9: MISCELLANEOUS PROVISIONS
32 §13781. Generic and therapeutically equivalent substitution
32 §13783. Posting prices (REPEALED)
32 §13784. Patient information regulation
32 §13785. Patient profile record system regulation
32 §13786. Identification of persons prescribing medicines on hospital prescription blanks
32 §13786-A. Security requirements; rules
32 §13786-B. Partial dispensing of prescription for opioid medication
32 §13786-C. Dispensing of prescription of opioid medication; immunity
32 §13786-D. Prescribing and dispensing insulin
32 §13786-E. Prescribing, dispensing and administering HIV prevention drugs
32 §13786-F. Dispensing of emergency supplies of chronic maintenance drug
32 §13787. Hypodermic syringes; prescriptions (REPEALED)
32 §13787-A. Sale of hypodermic apparatus
32 §13788. Sale of poisonous drugs
32 §13789. Possession of drug samples
32 §13790. Using drugs not in prescription
32 §13792. Sale by certain methods prohibited
32 §13793. Adulterating and selling drugs
32 §13794. Labeling of prescriptions
32 §13795. Photographic proof of identification; discretion to sell or dispense; immunity
32 §13796. Retail sale of targeted methamphetamine precursors
32 §13797. Prescription drug price information
32 §13798. Expedited partner therapy
32 §13799. Consumer choice preserved
32 §13800. Access to distributed drugs
32 §13800-A. Liability for product of another; exemption
32 §13800-B. Prohibition on providing conversion therapy to minors